



IN THE UNITED STATES PATENT & TRADE MARK OFFICE

In re Appl.: Savion N. : Group Art Unit: 1618
Serial No.: 09/341,048 : Examiner: Zhoreh Fay
Filed: August 9, 1999 :
For: TREATMENT OF THE EYE WITH A PHARMACEUTICAL COMPOSITION

AMENDMENT

Responsive to the Office Action of April 5, 2005, the period for responding being extended herewith to September 5, 2005, reconsideration and allowance of the claims is requested by the applicant in view of the following amendments and remarks.

IN THE TITLE

Please amend the title to read as follows.

-- TREATMENT OF THE EYE WITH A PHARMACEUTICAL COMPOSITION --.

IN THE CLAIMS

Please cancel claims 108-109, 112-113, 115-130 and 132, and substitute therefor the following claims.

Claims 108-109, 112-113, 115-130 and 132. (Canceled)

141. (Newly Added) A method of promoting healing or regeneration of damaged eye epithelium or cornea or of the anterior segment of the eye, comprising administering or applying to a subject afflicted with a disorder or condition associated with eye epithelium, cornea or anterior segment damage a therapeutic amount of an agent(s) comprising a high density lipoprotein (HDL), and/or a non-cholesterol lipid component(s) thereof able to reconstitute HDL.

142. (Newly Added) The method of claim 141, wherein the therapeutic amount of the agent(s) comprise(s) an eye epithelium regenerative amount thereof.

143. (Newly Added) The method of claim 141, wherein the agent comprises HDL, a phospholipids(s) and/or sphingolipid(s), a phospholipids(s) and at least one HDL lipid component(s) other than cholesterol and cholesteryl ester, at least one apolipoprotein(s) or a mixture thereof.

144. (Newly Added) The method of claim 141, wherein the disorder or condition comprises a corneal epithelial defect, membrane rupture, corneal damage associated with eye